Recent Updates
Recently added Catalysts
RIGL Neutral Sentiment

Rigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business Update

Tuesday, April 25, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Rigel Pharmaceuticals, Inc. has announced it will report its first quarter 2023 financial results on May 2, 2023, followed by a live conference call and webcast. Senior management will discuss the financial results and provide a business update during the call. Participants can access the live conference call and the webcast, which will also be archived for 90 days. Rigel is focused on developing therapies for hematologic disorders and cancer.
Price reaction · baseline $11.65 (2023-04-24 close) · hit after-hours · clean, no other RIGL news in the window
day 0 close · peak
-3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Rigel Pharmaceuticals will announce financial results and a business update.
  • The company has a focus on developing novel therapies for hematologic disorders and cancer.
  • A live webcast will allow broader access to the company's updates.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
12.1%
average across 2 past catalysts
Lead asset
Fostamatinib
Phase 2 · Acute Respiratory Distress Syndrome

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., April 25, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2023 financial results after market close on Tuesday, May 2, 2023. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.
Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com
Contact for Investors & Media:
Rigel Pharmaceuticals, Inc.

Frequently Asked Questions

When will Rigel Pharmaceuticals report its Q1 2023 financial results?

Rigel will report its Q1 2023 financial results on May 2, 2023, after market close.

What time is the Rigel conference call scheduled?

The conference call is set for 4:30 p.m. Eastern Time on May 2, 2023.

How can I access the conference call by Rigel Pharmaceuticals?

Participants can dial 877-407-3088 for domestic or 201-389-0927 for international access.

Where can I find the webcast of Rigel's financial results?

The webcast will be available on Rigel's Investor Relations section at www.rigel.com.

How long will the Rigel webcast be available for replay?

The webcast will be archived and accessible for 90 days after the call.

ShareAdd on Google
Tags: RIGL Viatris Investor Conferences Healthcare Rigel Pharmaceuticals financial results business update drug development Q1 2023
Last updated: Apr 25, 2023

Biotech snapshot

Cash runway
$95M liquidity · $0M/mo burn
Low dilution risk
Lead asset
FostamatinibPhase 2
Acute Respiratory Distress Syndrome →

Catalyst track record

+9%
best trade around RIGL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for RIGL.

See every catalyst's timing & PoA →